Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT)

Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 389, 815, 10.1016/S0140-6736(16)32401-1 Ahdoot, 2020, MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis, N Engl J Med, 382, 917, 10.1056/NEJMoa1910038 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 PRIAS project. Active surveillance. https://www.prias-project.org/. Feuer, 2021, Application of the PRECISION trial biopsy strategy to a contemporary magnetic resonance imaging-targeted biopsy cohort—how many clinically significant prostate cancers are missed?, J Urol, 205, 740, 10.1097/JU.0000000000001406 Wenzel, 2021, Correlation of MRI-lesion targeted biopsy vs. systematic biopsy Gleason score with final pathological Gleason score after radical prostatectomy, Diagnostics, 11, 882, 10.3390/diagnostics11050882 Luzzago, 2020, Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling, Urol Oncol, 38, 929.e11, 10.1016/j.urolonc.2020.05.027 Emmett, 2021, The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study, Eur Urol, 80, 682, 10.1016/j.eururo.2021.08.002 Uprimny, 2017, 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour, Eur J Nucl Med Mol Imaging, 44, 941, 10.1007/s00259-017-3631-6 Kalapara, 2022, Combined utility of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography and multiparametric magnetic resonance imaging in predicting prostate biopsy pathology, Eur Urol Oncol, 5, 314, 10.1016/j.euo.2021.02.006 Bhanji, 2022, New imaging modalities to consider for men with prostate cancer on active surveillance, World J Urol, 40, 51, 10.1007/s00345-021-03762-x Schoots, 2018, Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis, BJU Int, 122, 946, 10.1111/bju.14358 Turkbey, 2019, Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2, Eur Urol, 76, 340, 10.1016/j.eururo.2019.02.033 Ceci, 2021, E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET, Eur J Nucl Med Mol Imaging, 48, 1626, 10.1007/s00259-021-05245-y Wegelin, 2019, The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies, Eur Urol, 75, 582, 10.1016/j.eururo.2018.11.040 van Leenders, 2020, The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma, Am J Surg Pathol, 44, e87, 10.1097/PAS.0000000000001497 Harris, 2019, The REDCap consortium: building an international community of software platform partners, J Biomed Inform, 95, 103208, 10.1016/j.jbi.2019.103208 Kawada, 2022, Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis, Eur Urol Oncol, 5, 390, 10.1016/j.euo.2022.04.006 Rosenkrantz, 2016, Interobserver reproducibility of the PI-RADS version 2 Lexicon: a multicenter study of six experienced prostate radiologists, Radiology, 280, 793, 10.1148/radiol.2016152542 Ptasznik, 2022, High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer, BJU Int, 130, 5, 10.1111/bju.15736 Heetman, 2022, Clinically significant prostate cancer diagnosis without histological proof: a possibility in the prostate-specific membrane antigen era?, Eur Urol Open Sci, 44, 30, 10.1016/j.euros.2022.06.013 Teunissen, 2022, The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating “trials within cohorts” (TwiCs) for the evaluation of interventions for prostate cancer, World J Urol, 40, 2205, 10.1007/s00345-022-04092-2 Hoffman, 2020, Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer, JAMA, 323, 149, 10.1001/jama.2019.20675